Aug 19 (Reuters) - Spectral Medical Inc EDT.TO
* Spectral unaware of any material change
* Expects to release primary end point results for pivotal Euphrates trial immediately after end of Q3 ended September 30, 2016
* Confirms it is unaware of any material, undisclosed corporate developments that would account for recent decrease in its share price Source text for Eikon: Further company coverage: EDT.TO